The ZENITH trial demonstrated that among high-risk adults with PAH on maximum tolerated dose of background therapy, treatment with sotatercept resulted in a lower risk of all-cause death, lung ...

AZD0780, a novel, once-daily oral molecule inhibitor, had a robust, dose-dependent effect in lowering LDL-C and a favorable safety profile in patients with hypercholesterolemia already on background ...

"Refocusing and reframing the definition and discussion of coronary artery disease (CAD) from late-stage ischemia and acute coronary events to early detection of coronary artery atheroma and ...

Coronary atherosclerotic phenotypes, including total plaque volume (TPV), noncalcified plaque (NCP), calcified plaque (CP) and percentage atheroma volume (PAV), assessed by artificial ...

The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...

Sotatercept, a first-in-class novel activin-signaling inhibitor, led to a 76% lower risk of a composite of death from any cause, lung transplantation or hospitalization for worsening pulmonary ...

Patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke at five years, according to research presented during ...

One of the most significant modifications that middle-aged patients can take to prevent cardiovascular disease is lowering arterial hypertension, according to research presented during a Featured ...

Among patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD), the baseline estimated glomerular filtration rate (eGFR) did not impact the ...

The novel extended-duration small interfering RNA lepodisiran reduced mean serum concentrations of lipoprotein(a) (Lp[a]) from 60 to 180 days after being administered subcutaneously, according to ...

The HERZCHECK trial demonstrates the feasibility and diagnostic value of a mobile, CMR-based screening strategy for detecting asymptomatic stage B HF in rural, high-risk populations. Participants in ...

The ALIGN-AR trial contributes to the literature by demonstrating high technical success, a reassuring safety profile, and favorable clinical outcomes in high-risk patients with aortic regurgitation ...